3 results
Given the medical need for improved treatment strategies for patients with previously treated and relapsed MM, the purpose of this phase III study is to compare treatment with bortezomib/dexamethasone + panobinostat to bortezomib/dexamethasone +…
The primary objective is to characterize the change in the Pharmacodynamic (PD) biomarker, fecal calprotectin, during treatment with anrukinzumab.The secondary objectives include:* Characterization of the PK profile and total IL-13 of three multiple…
Primary Objectives- To replicate AVP-induced inhibition of anterior cingulate cortex (ACC) activity and functional connectivity as measured by BOLD fMRI during a face matching task. - To assess the effect of RO5285119 in the modulation of AVP…